Injectable · Skin Quality · Polynucleotide

Rejuran

How this page was made

This page was written with AI assistance and reviewed against the sources listed under References below. It is general information only, not medical advice. See our full disclaimer for how SHEA creates and reviews treatment information.

What it is

Rejuran is a Korean injectable brand manufactured by PharmaResearch and based on polynucleotide material derived from purified salmon DNA. It belongs to the broader group of injectable PDRN and polynucleotide treatments used for skin quality rather than being a generic name for the category.

Rejuran is sold in several variants intended for different treatment areas or uses, including Rejuran Healer, Rejuran I, and Rejuran S. Because formulations and intended uses can differ between products, ask the clinic which Rejuran product is being used.

See the PDRN & Polynucleotide page for more information about the broader treatment category and its underlying evidence.

Why people consider it

They are considering an injectable treatment aimed at skin quality rather than immediate volume or muscle relaxation
They are interested in changes in areas such as skin texture or elasticity
They are considering treatment around the eye area, where polynucleotide products have also been studied

What the experience is like

Rejuran is administered through multiple small injections into the skin. Clinics may use topical numbing before treatment. Temporary injection-site effects such as redness, swelling, bruising, or small raised areas can occur.

The number of sessions and spacing can vary according to the product, treatment area, and clinic protocol. Ask the treating clinic what protocol it uses rather than assuming a fixed treatment schedule.

Limitations & considerations

Evidence involving PDRN or polynucleotide treatments generally should not automatically be assumed to establish the same findings for Rejuran specifically or for every Rejuran variant
Rejuran is derived from salmon DNA, so a fish or seafood allergy should be disclosed to the treating clinic
Active skin infection or inflammation in the proposed treatment area should be discussed with the treating clinician before treatment
Safety during pregnancy or breastfeeding has not been established and should be discussed with the treating clinician
A history of keloid scarring is worth discussing with the clinician before injectable treatment
No specific cosmetic outcome can be guaranteed

Evidence note

Research on PDRN includes animal and laboratory studies investigating mechanisms involved in tissue repair. This mechanistic evidence should not be treated as direct evidence that Rejuran produces a particular cosmetic result in people.

A small randomized, double-blind, split-face clinical trial compared a polynucleotide treatment with a non-crosslinked hyaluronic acid filler for periocular rejuvenation. Its findings apply to the products, treatment area, and protocol studied and should not automatically be transferred to Rejuran generally or to other treatment areas.

A 2014 Phase III study comparing a polynucleotide filler with a hyaluronic acid filler for crow’s feet was retracted by the journal in 2016 following a conflict-of-interest disclosure issue. The retracted study is not used as supporting evidence on this page. The evidence summarized here therefore relies on other published research on PDRN and polynucleotides.

References

Peer-reviewed literature. The retracted publication is listed only to document its status and is not used as supporting evidence.

1. Galeano M, Bitto A, Altavilla D, et al. Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair and Regeneration, 2008;16(2):208–217.

Peer-reviewed · Animal study · Mechanism evidence

2. Veronesi F, Dallari D, Sabbioni G, et al. Polydeoxyribonucleotides (PDRNs) from skin to musculoskeletal tissue regeneration via adenosine A2A receptor involvement. Journal of Cellular Physiology, 2017;232(9):2299–2307.

Peer-reviewed · Mechanism review

3. Lee YJ, Kim HT, Lee YJ, et al. Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation: a randomized, double-blind, split-face trial. Journal of Dermatological Treatment, 2022;33(1):254–260.

Peer-reviewed · Randomized split-face trial (n=27) · Industry-supported

4. Pak CS, Lee J, Lee H, et al. A Phase III, Randomized, Double-Blind, Matched-Pairs, Active-Controlled Clinical Trial and Preclinical Animal Study to Compare the Durability, Efficacy and Safety between Polynucleotide Filler and Hyaluronic Acid Filler in the Correction of Crow’s Feet. Journal of Korean Medical Science, 2014;29(Suppl 3):S201–S209. Retracted 2016 — listed only to document the retraction and not used as supporting evidence.

Retracted · Not used as evidence